AMAG Pharma Shares Down 1.72%; Earlier Co. Reported Prelim. Q4 Adj. Sales $156M-$163M vs $161.09M Est., Operating Loss $6M-$16M, Adj. EBITDA $58M-$68M; Co. Sees FY17 Adj. Sales $613M-$620M vs $615.98M Est., FY18 Sales $500M-$560M vs $504.11M Est.